AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics

Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications

THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,257,071 (‘071 patent) titled Controlled sympathectomy and micro-ablation systems and methods. The newly issued ‘071 patent relates to, but is not necessarily limited to, advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation technologies, providing enhanced precision in treating nerve-related conditions. These systems allow for the identification and ablation of overactive nerves within the peripheral nervous system using a minimally invasive approach. The granted patent represents a significant step forward in Autonomix’s mission to improve patient outcomes by delivering more effective, less invasive treatments for neurological conditions such as chronic pain, hypertension and a myriad of other nerve-related disorders.

“We are excited to announce the issuance of this patent, marking a key milestone in our strategy to transform pain management and treat neurological disorders through minimally invasive, catheter-based denervation. This innovative technology enhances our intellectual property position in the rapidly growing nerve-focused therapeutics space, allowing us to protect our offerings and deliver improved solutions for both clinicians and patients. This patent is a vital addition to our expanding portfolio as we continue working toward our goal of revolutionizing the treatment of nerve-related conditions,” commented Brad Hauser, CEO of Autonomix.

In particular, the ‘071 patent covers key features of the technology including, but not necessarily limited to: Deployable microfingers with embedded sensors for real-time physiological monitoring; Ability to map, stimulate, ablate, and assess nerve activity in a single integrated system; Feedback-driven control of multiple types of procedures such as RF ablation, ultrasound, or chemical delivery; and Supports adaptive modulation to adjust therapeutic output in real-time based on inputs like EMG, MMG, and bioimpedance. The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, cardiac modulation and metabolic and neurological disorders.

Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.

The Company expects to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.

For more information about the Company’s technology, please visit .

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer, and timing of its submission of an IDE and the commencement of U.S. clinical trials. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”



Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
15/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the U...

 PRESS RELEASE

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Hu...

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain  Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or ...

 PRESS RELEASE

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerv...

 PRESS RELEASE

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bel...

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET Access the event THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the on Thursday, May 22, 2025 at 4:00 PM ET. As part of the event, of Autonomix, will provide a corporate overview and discuss the Company’s first-in-class platform system technology,...

 PRESS RELEASE

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansi...

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- –  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advan...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch